.png){kind=icon}
返回
M
Michael S. Hofman
Peter MacCallum Cancer Centre
78H指数
536论文数
2.6W被引数
收录论文 271
发表时间
.png){kind=icon}
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry原发性评分（PRIMARY Score）在分期前列腺特异性膜抗原正电子发射断层扫描中的应用与初诊前列腺癌患者总生存期的关系：国际、多中心PROMISE注册研究的结果.png)
European Urology.png)
OAAI
European UrologyIF25.2
OAAI.png){kind=icon}
分享.png){kind=icon}
收藏Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌（AlphaBet 研究）：一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析
PREAI
分享收藏Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial基线PSMA-PET总肿瘤体积和SUVmean在转移性去势抵抗性前列腺癌中的预后和预测价值：一项来自多中心、开放标签、随机、II期试验ENZA-p (ANZUP1901)的亚研究
PREAI
分享收藏First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果（VIOLET）：一项单中心、单臂、I/II期研究
PREAI
分享收藏